Abstract
Patient was a 65-year-old man who referred to cardiology service because of shortness of breath and an elevated BNP of 5450 ng/l. He had NYHA class 2. He did not appear congested on examination. Recently, he was diagnosed with biopsy confirmed AL (light chain) Amyloidosis after presentation with nephrotic syndrome.
ECG showed sinus rhythm with first-degree AV block, PACs, left axis deviation, Q wave in the inferior leads, PR interval 210 ms, QT interval of 490 ms, and Bi-fascicular block.
Chest x-ray was normal, he had elevated brain natriuretic peptide (BNP).
He underwent an echocardiogram, which showed LVEF 39%, increased biventricular wall thickness, increased cardiac valves thickness and relative apical sparing on GLS (Figs. 19.1 and 19.2). He also underwent cardiac MRI which showed mild to moderate late Gadolinium enhancement related to cardiac amyloidosis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989–95. https://doi.org/10.1200/JCO.2011.38.5724.
Gertz MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am J Hematol. 2020;95(7):848–60. https://doi.org/10.1002/ajh.25819.
Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357–77. https://doi.org/10.1161/CIRCULATIONAHA.116.024438.
Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–16. https://doi.org/10.1056/NEJMoa1805689.
Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ III, Colby CL, Therneau TM, Clark R, Kumar SK, Bradwell A, Fonseca R, Jelinek DF, Rajkumar SV. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet. 2010;375:1721–8.
Feng D, Syed IS, Martinez M, Oh JK, Jaffe AS, Grogan M, Edwards WD, Gertz MA, Klarich KW. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation. 2009;119(18):2490–7. Epub 2009 May 4. PMID: 19414641. https://doi.org/10.1161/CIRCULATIONAHA.108.785014.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Rohani, A. (2021). Amyloid Heart Disease. In: Clinical Cases in Cardio-Oncology. Clinical Cases in Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-71155-9_19
Download citation
DOI: https://doi.org/10.1007/978-3-030-71155-9_19
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-71154-2
Online ISBN: 978-3-030-71155-9
eBook Packages: MedicineMedicine (R0)